From the Archives: Bonus Content

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.

To complete the activity and claim free CME/NCPD, visit: https://i3health.com/mf

Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD

In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the May Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia (WM) session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.

Additional Advances in Waldenstrom Macroglobulinemia Research and Clinical Trials: Morie Gertz, MD

Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about what to look forward to from this year's ASH Annual Meeting.

Additional Advances in Multiple Myeloma Research and Clinical Trials: Sarah Holstein, MD, PhD

Visit https://i3health.com/relapsed-refractory-multiple-myeloma to book a live or virtual meeting at your own institution and hear more expert perspectives from Dr. Kumar or other esteemed multiple myeloma faculty!

Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.

Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD

In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.

Additional Advances in Squamous NSCLC Research and Clinical Trials With Mark Kris, MD

In 2022, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, recorded a CME/NCPD activity centered on new therapeutic avenues for improved patient outcomes in graft-versus-host-disease (GVHD). Recently, at the American Society of Hematology (ASH) Annual Meeting, she presented results of the BMT CTN 1703 trial, which investigated the efficacy of a GVHD prophylaxis regimen. While there, Dr. Holtan sat down with Oncology Data Advisor to discuss the potential of these results to change GVHD prophylaxis, as well as the other significant GVHD research presented at the meeting.  

Click here to view and claim credit for New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/gvhd

Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials: Shernan Holtan, MD

Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians.

Click here to complete the free CME/NCPD/CE activity: bit.ly/3HqXjpX

Additional Advances in Genetic Counseling and Testing in Cancer Care With Filipa Lynce, MD, and Catherine Skefos, MA, MS, CGC

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: bit.ly/45u106o

Click here to continue listening to Module 2 of this series: bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: bit.ly/3HtOziO

Click here to listen to Module 1 of this series: bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: https://bit.ly/45u106o

Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: https://bit.ly/3HtOziO

Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Last Chance: Multiple Myeloma Task Force Podcast

Don't miss your final opportunity to listen to this CME/NCPD-accredited podcast on Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma. Last chance to listen and claim credit is September 10, 2025.

Hear from Task Force Co-Chairs Dr. Sikander Ailawadhi (Mayo Clinic) and Dr. Rahul Banerjee (Fred Hutchinson Cancer Center/University of Washington) as they discuss strategies for improving patient outcomes and addressing healthcare disparities in relapsed/refractory multiple myeloma.

Click here to claim your CME/NCPD credit: https://bit.ly/4e25pQP

EXPIRING SOON! Mitigating Disease Burden and Healthcare Disparities in Multiple Myeloma

Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind 

ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool. 

From Abstracts to Action: How ASCOmind Streamlines Oncology Insights With Xiaoyan Wang, PhD; William Oh, MD; and Waqas Haque, MD, MPH

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit: https://bit.ly/488fPhK

Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit:

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials: Shernan Holtan, MD

Oncology Data Advisor®

Related tracks